Connecting clinical care, data and research
PartnershipsContact

RESEARCH & EDUCATION

The clinical trial paper published in Lancet Regional Health is expected to exceed 20 points next year!

The academic sharing record of the original official website; the content reflects the information of individual researchers or teams at the time of original publication.

This page is a historical sharing of the original official website. The research results, statistics and evaluations involved belong to individual researchers or teams at that time and do not represent the current overall results of the Society.

Original official website text record

Share this clinical trial paper that we recently published in Lancet Regional Health. This journal just got a score this year and is expected to have a chance to break through 20 points next year. This is a new JAK inhibitor, used to treat Chinese data on rheumatoid arthritis. It was sponsored by a Japanese pharmaceutical company. I participated in the design and planning, and was the result of a cross-border collaboration executed in mainland China. The results of the study: The effectiveness is roughly similar to the results in Western countries, but the new information is that the side effects of herpes zoster in Chinese areas are not that high. In other words, the safety of this new drug is relatively better.

Further reading:Original data (open in another window)

Return to Research and Education